Retatrutide
Retatrutide guides
Retatrutide is a triple hormone receptor agonist from Eli Lilly and Company, given as a once-weekly injection under the skin. 4 phase 3 trials have reported. It is not approved in Canada or anywhere else: no submission under review. Pick a question below. Each guide carries the date it was checked and a list of its sources.
Retatrutide: the drug and the trial data
-
What Is Retatrutide?
The first obesity drug to act on three hormone receptors at once, and what that third one adds.
Read guide -
Retatrutide Peptide
The 39-amino-acid molecule, why it lasts a week, and what the “research peptide” vials online really are.
Read guide -
Retatrutide Side Effects
Reported rates by dose from four phase 3 trials, how many people stopped, and the skin-sensation finding.
Read guide -
Retatrutide Dosage
The weekly doses the trials tested, how they stepped up, and why no approved dose exists.
Read guide
Retatrutide in Canada
-
Is Retatrutide Available in Canada?
Where it stands with Health Canada, the Canadian trial sites, and the approved options today.
Read guide -
Retatrutide Approval Timeline
Every dated step so far, and each one still to come before a Canadian pharmacy can fill it.
Read guide -
Buying Retatrutide in Canada
What the vials sold online are, what Health Canada has said about them, and the import rules.
Read guide